Clinical Trials for Allogene Therapeutics

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Allogene Therapeutics

Clinical Trials (8)

NCT07085104
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
PHASE1Recruiting
54 participants
Started: Sep 30, 2025 · Completed: Oct 31, 2032
4 conditions1 sponsor2 locations
NCT06925685
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
N/AEnrolling by invitation
50 participants
Started: Jan 31, 2025 · Completed: Jan 31, 2039
2 conditions1 sponsor1 location
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
PHASE2Recruiting
250 participants
Started: Jun 18, 2024 · Completed: Aug 24, 2031
1 condition2 sponsors53 locations
NCT05714345
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
PHASE2Active, not recruiting
70 participants
Started: Mar 31, 2023 · Completed: Oct 31, 2029
1 condition1 sponsor2 locations
NCT04696731
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
PHASE1Active, not recruiting
120 participants
Started: Feb 24, 2021 · Completed: Dec 31, 2025
1 condition1 sponsor10 locations
NCT04416984
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
PHASE1/PHASE2Active, not recruiting
160 participants
Started: May 21, 2020 · Completed: May 31, 2029
1 condition1 sponsor23 locations
NCT04093596
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
PHASE1Active, not recruiting
132 participants
Started: Sep 23, 2019 · Completed: Sep 30, 2027
1 condition1 sponsor11 locations
NCT03939026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
PHASE1Active, not recruiting
74 participants
Started: May 1, 2019 · Completed: Aug 31, 2026
2 conditions1 sponsor7 locations